RLB-SG-2026-00064 — RegLegBrief Citation

CITE THIS SIGNAL

RLB-SG-2026-00064

Guidance for Industry — Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTP (Version 6)

Issuing body Health Sciences Authority Jurisdiction SG Signal date 01 April 2026 Status Cited — Original document preserved by RLB Regulatory reference HSA Guidance for Industry — Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTP, Version 6, 1 April 2026 Document type Guidance

CITATION RELIABILITY

Hallucination-proof

RegLegBrief accessed the official regulatory portal directly and confirmed this document at source. This citation cannot be produced by any AI system.

Document-supported

This citation is supported by the original document, preserved by RegLegBrief in PDF format. PDF is used as the archival format because it is static and resistant to post-publication modification, unlike the original web or HTML source. The document can be independently accessed and verified against this citation at any time.

Permanent

The PDF is held permanently on RegLegBrief servers. This citation remains valid regardless of whether the original regulatory portal changes, restructures, or becomes unavailable.

Unique and immutable

This Citation ID is permanently and uniquely registered for this item in the RegLegBrief Citation Registry. It will never be reassigned, modified, or withdrawn.

GENERAL CITATION

RegLegBrief (reglegbrief.com) — Guidance for Industry — Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTP (Version 6) Regulatory reference: HSA Guidance for Industry — Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTP, Version 6, 1 April 2026 SG — 01 April 2026 Issuing body: Health Sciences Authority Status: Cited — Original document preserved by RLB Available at: https://reglegbrief.com/cite/RLB-SG-2026-00064 Citation ID: RLB-SG-2026-00064

DOCUMENTS

View cited item → https://reglegbrief.com/research/signals/sg/hsa/rlb-sg-2026-00064/guidance-industry-post-marketing-vigilance-requirements-therapeutic-products-ctgtp-version-6-hsa-6

Access preserved document → reglegbrief.com/cite/RLB-SG-2026-00064/document

reglegbrief.com/cite/RLB-SG-2026-00064